Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Investments (2018 - 2025)

Historic Long-Term Investments for Ascendis Pharma A (ASND) over the last 8 years, with Q3 2025 value amounting to $33.1 million.

  • Ascendis Pharma A's Long-Term Investments changed N/A to $33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.1 million, marking a year-over-year change of. This contributed to the annual value of $14.7 million for FY2024, which is 8770.76% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Long-Term Investments stood at $33.1 million.
  • Over the past 5 years, Ascendis Pharma A's Long-Term Investments peaked at $43.9 million during Q4 2021, and registered a low of -$12.3 million during Q1 2021.
  • Its 5-year average for Long-Term Investments is $19.5 million, with a median of $23.4 million in 2022.
  • As far as peak fluctuations go, Ascendis Pharma A's Long-Term Investments plummeted by 18886.09% in 2021, and later surged by 41988.82% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Long-Term Investments stood at $43.9 million in 2021, then tumbled by 46.66% to $23.4 million in 2022, then plummeted by 66.54% to $7.8 million in 2023, then soared by 85.32% to $14.5 million in 2024, then skyrocketed by 128.09% to $33.1 million in 2025.
  • Its Long-Term Investments stands at $33.1 million for Q3 2025, versus $39.5 million for Q2 2025 and $43.1 million for Q1 2025.